Category: Clinical Research

Sponsors still treat Uruguay as a soft Southern Cone add-on: “register after Argentina, same Spanish pack.” That sentence fails on the holder model. Uruguay’s MSP runs a strict single-Local-Holder regime: the Local Holder is the only entity authorised to import the registered device. If two Uruguayan distributors want to sell the same product, each needs its own separate registration. There is no multi-importer shortcut on one certificate.

I am Julio Martinez-Clark, CEO of bioaccess®. This page is the commercial Uruguay file: how a medical device gets onto the Uruguayan market under the Ministerio de Salud Pública (MSP), what Decreto N° 3/008 does for productos médicos, and why manufacturer-funded processing matters when the holder and importer seats are fused. It sits next to our LATAM market-access hub, the Uruguay MSP country page, and the Importer of Record guide. Operator guidance only. Not a quote and not legal advice.

One-sentence answer

Commercial sale in Uruguay requires MSP sanitary registration / venta authorization for the medical product under the device framework operators plan against Decreto N° 3/008, held by a locally enabled Local Holder who is also the only authorised importer for that registration — parallel holders may exist across separate filings, but one certificate does not authorize a second importer.

Two Uruguay desks — do not merge them

Investigational use. Research involving human subjects and device clinical evaluation under instruments such as Decreto 158/019, plus MSP/DIGESA study authorization where required. That file is not a license to sell. Our Uruguay CRO page already separates FIH execution from commercial MSP registration.

Commercial path. Registro and authorization to sell a medical product configuration on the Uruguayan market. The Local Holder on that certificate is the sanitary face and the import face. Downstream commercial relationships can exist; customs and MSP will still look for the holder authorised on the registration.

If your Gantt has one bar labeled “Uruguay MSP,” check whether you are clearing investigational units or commercial stock. Those are two work packages.

What the single-Local-Holder rule actually means

Our live market-access and Importer of Record pages treat Uruguay as one of the most restrictive Southern Cone holder designs:

• The Local Holder is the only entity authorised to import the registered device
• Registration ownership is not divisible across an open importer list
• If two distributors need to market the same product, each files its own separate registration
• Whoever pays for the registration controls it — a distributor that funds the filing can refuse transfer later

That is a different architecture from Colombia (titular with several importers) or Brazil (single detentor who can authorize multiple importadores). Do not copy an INVIMA or ANVISA multi-importer LOI onto Uruguay.

What belongs in the commercial dossier (operator list)

Exact MSP forms and DIGESA / Evaluación de Tecnología checklists move with current practice. The working stack sponsors assemble before Spanish production starts is stable:

• Device identity, intended use, and risk class as Uruguay will see it
• Manufacturer and manufacturing sites, with quality-system evidence appropriate to class
• Technical evidence already used for FDA or CE, mapped to the Uruguayan petition — not dumped as a zip of US folders
• Labels and IFU in Spanish for the configuration you will sell
• Local Holder appointment, representante legal, and director técnico documentation as the current MSP forms require
• Import story that matches the Local Holder — Uruguay fuses holder and importer on the commercial certificate
• Tecnovigilancia / post-market ownership under the holder while the product remains on the market

Public MSP trámite materials describe online initiation, product-type forms, and arancel payment for registro / autorización de venta. Confirm the live form codes for your product type before translators start. Electrical/EMC or RF homologation for wireless devices, when required, runs through Uruguay’s telecom authority as a separate vendor track.

What this file is not

• It is not a clinical-trial authorization under Decreto 158/019 or a FIH ethics pack.
• It is not MERCOSUR mutual recognition that invents one shared registration with Argentina, Brazil, or Paraguay. National MSP registro still sits on its own petition.
• It is not a flat annual bioaccess® holder subscription SKU. The live Uruguay country page sells manufacturer-funded registration processing because the Local Holder must also be the importer — there is no annual holder fee to quote the way Chile or Peru holder products are packaged.

How bioaccess® runs the Uruguay seat

On the live market-access offer, bioaccess® processes your MSP registration funded by you, the manufacturer — dossier, translations, agency liaison — while the Local Holder / importer face is structured with transfer-upon-demand clauses in the distribution agreement (reviewed by local counsel). Uruguay sits outside the standard LATAM Launch Subscription card on the country page; scope and timeline are confirmed at proposal. We do not invent a statutory day-count here.

Operator checklist before you open a Uruguay MSP folder

1. Write “trial” and “commercial” on two pages if you still need human data in Uruguay.
2. Decide the Local Holder before you pick a second distributor — a second commercial partner usually means a second registration.
3. Confirm manufacturer-funded processing so the channel does not own the certificate by default.
4. Align Spanish labels and IFU to the sellable configuration.
5. Name representante legal and director técnico owners on the local entity paperwork.
6. Budget telecom / RF tracks separately when the device is wireless.
7. If Argentina or Brazil is already on the launch list, do not assume Uruguay rides the same holder architecture.

Talk with bioaccess® when you need Uruguay MSP registration processed without handing the certificate to the first distributor — or when you are sequencing a Uruguay FIH into a later commercial file without mixing the desks.

Sponsors still write “Dominican Republic registration” as if DIGEMAPS were a customs stamp you buy after you pick a local reseller. It is not. DIGEMAPS names a single local Authorized Representative on each sanitary certificate. That party is the commercial face of the device for import, distribution, and post-market work under the Dominican rules — and if the distributor funds the filing, they usually own the number.

I am Julio Martinez-Clark, CEO of bioaccess®. This page is the commercial Dominican Republic file: how a medical device gets onto the market under DIGEMAPS (Dirección General de Medicamentos, Alimentos y Productos Sanitarios), what Decreto 82-15 and Decreto 246-06 actually do, and why the Authorized Representative seat is the decision you make before you sign an exclusive LOI. It sits next to our LATAM market-access hub, the DIGEMAPS country page, and the Importer of Record guide. Operator guidance only. Not a quote and not legal advice.

One-sentence answer

Commercial sale in the Dominican Republic requires DIGEMAPS sanitary registration with a single local Authorized Representative named on the certificate under the framework created by Decreto 82-15 (6 April 2015) and the substantive registration, import, distribution, and post-market rules in Decreto 246-06 — foreign manufacturers do not hold the number themselves, and transferring the local Authorized Representative role to a different Dominican entity needs DIGEMAPS approval.

Two Dominican desks — do not merge them

Investigational use. Ethics and clinical-research authorization for first-in-human or other device studies in the Dominican Republic. That file is not a license to sell. Keep trial import and commercial freight on separate accountability logs.

Commercial path. Manufacture, import, commercialization, or distribution of a device configuration you intend to sell. DIGEMAPS is the sanitary authority for that track. The certificate names one local Authorized Representative. Downstream sales partners can exist commercially; at the regulatory level there is one accountable local face per registration.

If your Gantt has one bar labeled “DIGEMAPS,” check whether you are asking for a trial petition or a selling license. Those are two work packages.

What Decreto 82-15 and Decreto 246-06 actually do

Decreto 82-15 created DIGEMAPS by merging the prior Drugs/Pharmacies and Food Risk Control directorates. It is the institutional home of the device sanitary file today — not a synonym for “MISPAS paperwork” generically.

Decreto 246-06 is the substantive rule set operators plan against for registration, import, distribution, and post-market duties. Do not invent a second Dominican statute number for a board slide. Plan against those instruments and current DIGEMAPS practice, and confirm forms before translators start.

Our live Importer of Record map treats the Dominican Republic as a single-Authorized-Representative market: one local AR per registration. Transferring that seat is not a private vendor swap. DIGEMAPS approval adds friction when you reshuffle commercial partners after launch.

What belongs in the commercial dossier (operator list)

Exact DIGEMAPS forms move with current practice. The working stack sponsors assemble before Spanish production starts is stable:

• Device identity, intended use, and Dominican risk class as DIGEMAPS will see it (commonly discussed as Class I / IIa / IIb / III — classify in the Dominican rule set; do not paste a US Class II memo)
• Manufacturer and manufacturing sites, with quality-system evidence appropriate to class
• Technical evidence already used for FDA or CE, mapped to the DIGEMAPS petition — not dumped as a zip of US folders
• Labels and IFU in Spanish for the configuration you will sell
• Local Authorized Representative appointment and Dominican entity documentation
• Import story that matches the named AR / importing face on the certificate — not a freight forwarder with a borrowed tax ID
• Tecnovigilancia ownership under the holder of the sanitary file

Operators also treat local trademark readiness (ONAPI) as a pre-file gate on many Dominican device petitions. Confirm the live DIGEMAPS checklist for your SKU before you pretend the sanitary clock has started. Electrical/EMC or RF homologation for wireless devices, when required, runs through the Dominican telecom authority as a separate vendor track. Do not bury that inside the DIGEMAPS sanitary clock.

What this file is not

• It is not a clinical-trial authorization. Trial units and commercial units follow different petitions.
• It is not “the distributor will handle registration.” In a single-AR market, whoever pays for and holds the certificate controls market access until DIGEMAPS approves a transfer.
• It is not an FDA or CE equivalence stamp. Prior clearances help the technical story; they do not replace DIGEMAPS registro for a commercial SKU.

How bioaccess® runs the Dominican seat

On the live market-access offer, bioaccess® sells DIGEMAPS registration processing funded by the manufacturer — dossier, translations, agency liaison, and hostage-proof contracting language for the distribution agreement — while the Dominican Authorized Representative / importer face sits on a structure that can transfer on demand. The Dominican Republic is not packaged as the standard annual LATAM Launch holder subscription on the country page; timelines are confirmed at proposal against the current DIGEMAPS queue. We do not invent a statutory day-count here. Public operator summaries often cite multi-month review windows for new applications; treat those as planning ranges until your proposal locks a submission schedule.

Operator checklist before you open a DIGEMAPS folder

1. Write “trial” and “commercial” on two pages if you still need human data in the Dominican Republic.
2. Name the local Authorized Representative before you sign an exclusive distribution LOI.
3. Confirm who pays for the filing — manufacturer-funded processing is how you keep control of the certificate.
4. Align Spanish labels and IFU to the sellable configuration, not an investigational kit.
5. Confirm ONAPI / trademark readiness and any DIGEMAPS pre-file checklist items for your class.
6. Budget telecom / RF tracks separately when the device is wireless.
7. Write the transfer-upon-demand clause with local counsel before the first commercial shipment.

Talk with bioaccess® when you need DIGEMAPS registration processed independent of the commercial channel — or when you are sequencing a Dominican FIH into a later commercial file without mixing the desks.

Sponsors still treat Peru as “find a droguería and hope DIGEMID likes the dossier.” That sentence mixes three seats: the titular on the sanitary registration, the importer that holds a CRS / droguería license, and the commercial distributor that wins hospital tenders. Decreto Supremo N° 001-2024-SA is what lets you keep the first seat independent of the second and third.

I am Julio Martinez-Clark, CEO of bioaccess®. This page answers the market-access question — how a medical device gets onto the Peruvian market under DIGEMID (Dirección General de Medicamentos, Insumos y Drogas) — and how an independent Peru Registration Holder (PRH) keeps channel changes from becoming a new registration project. It sits next to our LATAM market-access hub, the Peru DIGEMID country page, and the Importer of Record guide. Operator guidance only. Not a quote and not legal advice.

One-sentence answer

Commercial sale in Peru requires DIGEMID sanitary registration held by a locally enabled titular, with imports flowing through a licensed droguería — and under Decreto Supremo N° 001-2024-SA an independent Peru Registration Holder can sit separate from the distributor, while additional droguerías can obtain their own CRS to import a product already registered by another titular.

Three Peru seats — write them on separate pages

Titular / PRH. The sanitary face of the device on the DIGEMID file. This is who answers for the registration and for tecnovigilancia obligations under DS 013-2014-SA (named Responsable de tecnovigilancia, DIGEMID-format incident reports, corrective actions, distribution list). If that system fails, DIGEMID can fine (published ceilings reference UIT units) and suspend or cancel the registration. A device without a live registration cannot legally stay on the market.

Importer / droguería. Licensed storage and import capacity. Additional droguerías can, under the 001-2024-SA model described on our live Peru page, obtain their own CRS to import a product already registered by another titular — which is why an independent PRH is useful and a distributor-titular is expensive to unwind.

Commercial distributor. Sales, tenders, and field relationships. This seat should not own the sanitary number if you want the option to change channel later.

If your LOI makes the first Peruvian distributor the titular “to keep it simple,” you have not simplified. You have priced a future cesión into the deal.

What belongs in the commercial dossier (operator list)

Exact DIGEMID forms move with current practice. The working stack sponsors assemble before translators start is stable:

• Device identification, intended use, and risk class as DIGEMID will see it
• Manufacturer and manufacturing sites, with quality-system evidence appropriate to class (ISO 13485 is the practical language)
• Technical file / essential-requirements evidence already used for FDA or CE, mapped to the Peruvian petition — not dumped as a zip of US folders
• Labels and IFU in Spanish for the configuration you will sell
• Independent PRH appointment and local entity documentation
• Importer / droguería CRS story that matches who will physically import — which may be more than one licensed actor over the life of the registration
• Tecnovigilancia ownership under the holder, with a named Responsable de tecnovigilancia on file

Electrical/EMC or RF homologation for wireless devices, when required, runs through Peru’s telecom authority as a separate vendor track. Do not bury that inside the DIGEMID sanitary clock.

What this file is not

• It is not a clinical-trial authorization. First-in-human and other investigational use follow a different petition set.
• It is not “the distributor will handle registration.” Under 001-2024-SA you can — and usually should — keep PRH independent of the commercial channel.
• It is not a free pass from tecnovigilancia. Holding the number without the Responsable and the DIGEMID reporting clocks is how registrations die after launch.

How bioaccess® runs the Peru holder seat

On the live market-access offer, bioaccess® acts as the neutral Peru Registration Holder through our own Peruvian entity for sanitary registration, importer-of-record coordination under the droguería pathway, sworn translations, government fees, and tecnovigilancia as holder. Pricing for the LATAM Launch Subscription is published on bioaccessla.com/market-access (USD 7,500 per year per country for the first device family; additional families at the published add-on rates). Timelines are confirmed at proposal against the current DIGEMID queue — we do not invent a statutory day-count here.

Operator checklist before you open a Peru registro folder

1. Write “titular,” “droguería/importer,” and “distributor” on three pages. Put owners and statutes on each page.
2. Decide the independent PRH before you sign an exclusive distribution LOI.
3. Confirm the configuration you will sell matches the labels and IFU you will file — not an investigational configuration from an FIH.
4. Map FDA/CE evidence to the DIGEMID petition; do not ship the US zip as the dossier.
5. Name the Responsable de tecnovigilancia and the complaint-forwarding clock from the US system into Peru before first commercial shipment.
6. Budget how a second droguería would obtain its own CRS if you add a second importer later — that is the point of 001-2024-SA.

Talk with bioaccess® when you need Peru registro held independent of the commercial channel — or when you are sequencing a Peru FIH into a later DIGEMID market file without mixing the desks.

Sponsors still write “Chile registration” as if ISP ran a single on/off switch. It does not. Some device categories already need sanitary registration. Many others still enter through a Certificado de Destinación Aduanera (CDA). Decreto Exento No. 25 of 2026 is expanding the mandatory list on a staged calendar — and Boletín 17.375-11, the broader risk-based reform bill, is not law yet.

I am Julio Martinez-Clark, CEO of bioaccess®. This page is the commercial Chile file: how a medical device gets onto the Chilean market under the Instituto de Salud Pública (ISP), when CDA is still enough, and how Decreto Exento No. 25 changes the planning calendar. It sits next to our LATAM market-access hub, the Chile ISP country page, and the Importer of Record guide. Operator guidance only. Not a quote and not legal advice.

One-sentence answer

Commercial sale in Chile requires ISP sanitary registration when your device category is under the sanitary-control regime of Article 111 of the Código Sanitario and Decreto Supremo No. 825 of 1998 — including the 39 categories Decreto Exento No. 25 of 6 March 2026 (Diario Oficial 19 March 2026) is pulling in on 24- and 36-month transition dates — while devices still outside a mandatory category typically import under a CDA until their category’s clock starts.

Two Chile desks — do not merge them

Investigational use. Ethics and clinical-research authorization for first-in-human or other device studies. That file is not a license to sell. Chile’s ethics timing and ISP research facts live on our Chile FIH / ethics pages, not on this commercial brief.

Commercial path. Manufacture, import, commercialization, or distribution of a device that already has a clearance story elsewhere (often FDA or CE). For categories already under sanitary control — and for categories Decreto Exento No. 25 will make mandatory after their transition dates — the conformity verification for that purpose is an ISP registro sanitario. For devices not yet in a mandatory category, ISP and Aduanas still use the CDA pathway for customs destination of unregistered devices.

If your Gantt has one bar labeled “ISP,” check whether the product is on a mandatory list today, on Decreto Exento No. 25’s 2028/2029 waves, or still CDA-only. Those are three different work packages.

What Decreto Exento No. 25 actually does

Published in the Official Gazette on 19 March 2026 (CVE 2781436), Decreto Exento No. 25 incorporates listed medical devices and IVDs into the sanitary-control regime under Article 111 of the Código Sanitario and DS No. 825/1998. Once each category’s transitional date arrives, those products may only be manufactured in Chile, imported, marketed, or distributed if they hold the corresponding ISP sanitary registration.

Planning anchors from the decree and the public transition tables operators are using in 2026:

• Technical instructives / complementary resolutions — target window within about 12 months of publication (around March 2027)
• Higher-risk / implantable wave — about 24 months (around 19 March 2028) for the first listed group
• Equipment, IVDs, SaMD, and remaining listed categories — about 36 months (around 19 March 2029)
• Voluntary early filing — the decree allows voluntary ISP registro before a category’s mandatory date once the instructivo técnico exists

Do not treat those dates as “we can ignore Chile until 2028.” Distributor selection, Spanish labeling, and holder appointment take longer than a board slide admits — and voluntary early registro is often the cleaner commercial story for US/EU manufacturers already shipping into Chile under CDA.

Boletín 17.375-11 is not the current rule

The broader bill that would move Chile toward open-ended, risk-based device authorization and put recognition of foreign approvals on a clearer statutory footing is Boletín 17.375-11. It is still a bill. Plan against Decreto Exento No. 25, DS No. 825/1998, and current ISP practice. Do not promise a board that Chile already runs a full IMDRF-style reliance regime for every class.

What belongs in the commercial dossier (operator list)

Exact ISP forms and instructivos move with ANDIM practice. The working stack sponsors assemble before translators start is stable:

• Device identity, intended use, and whether the product sits in a mandatory category today or on a Decreto Exento No. 25 wave
• Manufacturer and manufacturing sites, with quality-system evidence appropriate to the claimed category
• Technical evidence already used for FDA or CE, mapped to ISP’s petition — not dumped as a zip of US folders
• Labels and IFU in Spanish for the configuration you will sell
• Local legal entity / holder documentation — Chile’s commercial face of the file
• A written CDA-versus-registro decision for every SKU you intend to import before its mandatory date

Electrical/EMC or RF homologation for wireless devices, when required, runs through Chile’s telecom authority (SUBTEL) as a separate vendor track. Do not bury that inside the ISP sanitary clock.

What this file is not

• It is not a clinical-trial authorization. Trial units and commercial units follow different petitions.
• It is not a CDA forever. A CDA for an unregistered device is not a substitute for ISP registro once the category is mandatory.
• It is not Boletín 17.375-11. Do not sell “future recognition of FDA” as today’s pathway.

How bioaccess® runs the Chile holder seat

On the live market-access offer, bioaccess® holds and manages Chilean registrations through our own local entity for sanitary registration, importer-of-record duties, sworn translations, government fees, and holder-side post-market work. Pricing for the LATAM Launch Subscription is published on bioaccessla.com/market-access (USD 7,500 per year per country for the first device family; additional families at the published add-on rates). Timelines on the Chile page are typically 30–90 days experience-based planning ranges once the dossier is ready — confirmed at proposal against the current ISP queue. We do not invent a statutory day-count here.

Operator checklist before you open a Chile registro folder

1. Map every SKU to mandatory-today, Decreto Exento No. 25 wave (2028/2029), or CDA-only.
2. Write “trial” and “commercial” on two pages if you still need human data in Chile.
3. Decide the local holder before you pick a distributor.
4. Confirm the sellable configuration matches Spanish labels and IFU — not an investigational configuration.
5. Budget SUBTEL / RF tracks separately when the device is wireless.
6. If you are already selling under CDA into a category on the 2028/2029 waves, decide whether voluntary early registro is cheaper than a scramble later.

Talk with bioaccess® when you need Chile registro held independent of the commercial channel — or when you are sequencing a Chile FIH into a later ISP market file without mixing the desks.

US MedTech founders ask this in almost every Panama or El Salvador first-in-human (FIH) scoping call: “If we run the early cases outside the US, will FDA take the data for an IDE, 510(k), De Novo, or PMA?”

I am Julio Martinez-Clark, CEO of bioaccess®. Short answer: yes, foreign clinical data can support those files — when you design the study for 21 CFR 812.28 from day one. A fast ethics letter on the wrong protocol is not an FDA asset. This page is the operator cut for Panama and El Salvador. It sits next to our Panama FIH Class III guide, the LATAM vs Australia early-feasibility comparison, and the early feasibility vs pivotal brief. Not a quote and not legal advice.

One-sentence answer

Panama or El Salvador FIH data can enter an FDA strategy when the investigation meets the good clinical practice (GCP) and supporting-information rules in 21 CFR 812.28 — including an inspectable trial file — and when the investigational device is identical to the US device or you submit a detailed comparison.

What 21 CFR 812.28 actually tests

FDA’s foreign-clinical-data rule is not a country whitelist. It asks whether the investigation was conducted under a GCP standard for design, conduct, monitoring, auditing, recording, analysis, and reporting that keeps data credible and protects subjects. That standard includes independent ethics-committee review and approval before initiation, continuing review, and documented freely given informed consent.

FDA has stated that conformance with ISO 14155:2020 will generally satisfy the GCP requirement of 812.28. Investigations initiated on or after 21 February 2019 must conform to the 2018 foreign-data framework. Country of conduct is relevant for import, ethics, and site quality. It is not a substitute for 812.28 design.

Significant-risk devices: build the full 812.28(b) set

For a significant-risk device as defined in 21 CFR 812.3(m) — the Class III / high-risk biomaterial FIH case — plan the full supporting set in 812.28(b):

• Investigators and sites
• Protocol and results
• A statement that the investigational device is identical to the US device, or a detailed comparison of differences
• Valid scientific evidence under 21 CFR 860.7 if you claim safety and effectiveness
• Independent ethics committee (IEC) identity meeting 812.3(t)
• Consent, monitoring, and investigator GCP training documentation

FDA can validate the data through an onsite inspection or other appropriate means. A Panama or El Salvador file that cannot be inspected is not an 812.28 file. Electronic data capture, device accountability, and source documents that survive an English-speaking inspector are part of study design — not a later translation job.

Do not plan to live in 812.28(e)

Section 812.28(e) is the residual clause: even when a foreign study does not fully meet paragraph (a), FDA may still accept the information if it believes the data are credible and accurate and that subject rights were adequately protected. That is a reviewer safety valve. It is not a protocol strategy. Build paragraph (a). Treat (e) as the exception you hope never to need.

Why Panama and El Salvador show up in the same answer

Both countries are used for early device cohorts when sponsors need surgical or hospital volume outside a US IDE queue. Panama’s investigational desk runs under Ley 84 of 2019 and Decreto Ejecutivo No. 21 of 2026 (CNBI-accredited Type II ethics, RESEGIS, parallel MINSA review for higher-risk protocols). El Salvador is often the second country in a multi-country early plan when enrollment or anatomy needs a wider net — the same pattern already described on our Panama FIH guide (Panama plus El Salvador plus Brazil as an example multi-country frame).

For FDA usability, the country pair matters less than whether both sites run one protocol, one monitoring plan, one device configuration, and one TMF standard. Two local “quick starts” with divergent ICFs and unaccounted devices will not stitch into an 812.28 package later.

What makes OUS data fail the FDA conversation

• Protocol written for local approval only, with inclusion, imaging, and device deficiencies redefined after the fact for a US file
• Investigational configuration that quietly differs from the US device without a comparison table
• English-only or incomplete source that cannot support inspection
• Mixing commercial registro (Panama DNDM / Ley 90–Decreto 490) with the trial authorization and assuming market clearance equals clinical evidence
• Hoping 812.28(e) will rescue a study that never ran ISO 14155 discipline

Operator checklist before first patient in Panama or El Salvador

1. Write the US intended use and device configuration on one page. Lock whether the OUS unit is identical or document every difference.
2. Design the protocol once for ISO 14155:2020 monitoring, consent, and SAE clocks — then map local ethics and ministry steps underneath it.
3. Confirm ethics committees meet the independence expectations behind 812.3(t) and keep approval letters in the TMF.
4. Build EDC, device accountability, and source so an FDA inspector can follow a subject without a scavenger hunt.
5. Keep commercial registro off the FIH critical path. Trial authorization is not a license to sell.

Talk with bioaccess® when you need a Panama or El Salvador FIH framed so the same dataset can later support an IDE conversation or a marketing submission under 21 CFR 812.28 — without inventing a country whitelist FDA does not publish.

Sponsors keep mixing two Panama desks into one email: “we need MINSA for our device.” One desk is commercial registro sanitario. The other is clinical-research authorization. They are not the same petition, and swapping them mid-cycle is how a quarter disappears.

I am Julio Martinez-Clark, CEO of bioaccess®. This page answers the market-access question — how a medical device gets onto the Panamanian market under MINSA’s Dirección Nacional de Dispositivos Médicos (DNDM) — and how that file stays off the first-in-human critical path. It sits next to our LATAM market-access hub, the Importer of Record guide, and the Panama FIH device guide. Operator guidance only. Not a quote and not legal advice.

One-sentence answer

Commercial sale in Panama is a sanitary-registration file under Ley 90 of 26 December 2017 (as modified by Ley 92 of 12 September 2019) and Decreto Ejecutivo No. 490 of 4 October 2019, with DNDM as the classifying authority and a single Authorized Representative as the regulatory anchor. A MINSA/CNBI trial authorization is not a license to sell.

Two MINSA desks — write them on separate pages

Investigational use. Protocol review under Ley 84 of 14 May 2019 and Decreto Ejecutivo No. 21 of 23 April 2026 (Gaceta Oficial No. 30510-C), with ethics at a CNBI-accredited Type II committee and RESEGIS registration before start. That path is for first-in-human and other clinical research. See the Decreto 21 explainer.

Commercial registro. Sale and distribution of a medical device that already has a clearance story elsewhere (often FDA or CE) follows Ley 90 / Ley 92 and Decreto 490. Risk class for registro sanitario follows current GHTF/IMDRF rules; DNDM classifies. The named Authorized Representative is the regulatory face of the product and, in Panama’s single-representative model, the importer-of-record anchor.

If your Gantt has one bar labeled “MINSA,” you do not have a plan. You have a hope.

What the single Authorized Representative model means

Panama is a single-representative market. The representative on the registro is the sanitary face of the device. Changing that name is closer to a new market entry than a contract amendment — the same pattern we describe for other single-AAR Central American markets on the independent registration-holder strategy page.

Design implication for US and European manufacturers: do not put the commercial distributor on the certificate if you want the option to change channel later. Hold titularidad with an entity that answers to the manufacturer’s transfer doctrine — then authorize distributors underneath that holder.

What belongs in the commercial dossier (operator list)

Exact forms and annexes move with DNDM practice. The working stack sponsors assemble before translators start is stable:

• Device identification, intended use, and GHTF/IMDRF risk class as DNDM will see it
• Manufacturer and manufacturing sites, with quality-system evidence appropriate to class
• Technical file / essential-requirements evidence already used for FDA or CE, mapped to the Panamanian petition — not dumped as a zip of US folders
• Labels and IFU in Spanish for the configuration you will sell
• Authorized Representative appointment and local entity documentation
• Tecnovigilancia ownership under the holder, not under whichever distributor won the first tender

Electrical/EMC or RF homologation for wireless devices, when required, runs through Panama’s telecom authority as a separate vendor track. Do not bury that inside the sanitary clock.

What this file is not

• It is not a substitute for Decreto 21 ethics + MINSA research review when you still need human data.
• It is not an investigational import permit. Trial units enter under the research authorization; commercial units enter under registro.
• It is not a free pass to use a Panama FIH as proof of market clearance. First patient in and registro sanitario are different end states.

How bioaccess® runs the Panama holder seat

On the live market-access offer, bioaccess® acts as the Panamanian Authorized Representative through our own local entity for sanitary registration, importer-of-record duties, sworn translations, government fees, and tecnovigilancia as holder. Pricing for the LATAM Launch Subscription is published on bioaccessla.com/market-access (USD 7,500 per year per country for the first device family; additional families at the published add-on rates). Timelines are confirmed at proposal against the current DNDM queue — we do not invent a statutory day-count here.

Operator checklist before you open a Panama registro folder

1. Write “trial” and “registro” on two pages. Put owners and statutes on each page.
2. Decide the Authorized Representative before you pick a distributor.
3. Confirm the configuration you will sell matches the labels and IFU you will file — not the investigational configuration from an FIH.
4. Map FDA/CE evidence to the DNDM petition; do not ship the US zip as the dossier.
5. Budget tecnovigilancia and holder change cost as part of channel design, not as a later surprise.

Talk with bioaccess® when you need Panama registro held independent of the commercial channel — or when you are sequencing a Panama FIH under Decreto 21 into a later DNDM market file without mixing the desks.

Founders keep asking which early-feasibility destination is cheaper and faster: Latin America or Australia. They want a single winner. There is not one.

I am Julio Martinez-Clark, CEO of bioaccess®. This is the comparison I reuse when a US MedTech team has already heard the Australia CTN story and the LATAM cost story, and needs a decision frame instead of a brochure. It sits next to the live Australia vs Latin America FIH note and the Early Feasibility Studies pillar.

One-sentence answer

Latin America is usually cheaper per patient and can be faster to first patient when the dossier, ethics stack, and import plan are built for the country you chose. Australia stays faster to start when you need an English academic workflow and you are not ready to run a Spanish or Portuguese trámite. Neither wins if the protocol cannot support the FDA conversation you need next.

Cheaper is not the same as lower total cost

Per-patient cost in Colombia or Panama is often in a planning band about 40–60% below a comparable US or Australian number for similar procedure work. That band is experience-based from bioaccess® programs since 2010 — not a quote for your protocol.

Total program cost only wins if you do not pay for a second early feasibility study because the first one was exploratory in a way FDA later ignores. A cheaper study that cannot travel into an IDE conversation under 21 CFR 812.28 is a redo, not a savings.

Faster depends on which clock you mean

Australia. CTN/CTX and English ethics make the path look short. The CTN is often not the critical path. Site contracting, device import, and hospital activation still stack. Sponsors who budget “12 weeks to first patient in” from a CTN slide routinely discover the bottleneck was logistics.

Latin America. There is no single LATAM clock. Colombia (INVIMA), Brazil (ANVISA), Mexico (COFEPRIS), Argentina (ANMAT), and Panama (MINSA / CNBI-accredited ethics) have different ethics and regulator stacks. Panama’s ethics-committee-driven pathway for many early device studies can land in a planning band of about 3–5 months from submission to first patient when the file is complete. Colombia’s CEI clock and INVIMA clock are not the same clock. Pick the country before you translate the packet.

Four filters that decide the winner

1. Language and dossier. Australia keeps an English core. LATAM usually does not. INVIMA’s traducción oficial is not a certified PDF from a US vendor. Plan translation from the source language on day one.

2. Ethics vs regulator. In both regions, ethics can move while another gate is still open. In Australia, HREC approval does not mean the site is open. In Colombia, ethics clearance is not INVIMA authorization. In Panama, Decreto Ejecutivo No. 21 of 2026 (Gaceta Oficial No. 30510-C) sets RESEGIS registration and Type II ethics accreditation as process gates — not as a reason to skip import planning.

3. Import and device custody. A first-in-human implant or catheter does not travel like a pill. Importer of record, customs, and cold chain decide whether first patient slips after every approval is “done.”

4. FDA usability. Foreign clinical data can support an IDE conversation when protocol, monitoring, and endpoints were written for that use under 21 CFR 812.28 and ISO 14155. Acceptance is still FDA’s call per submission.

When Australia is the better early-feasibility pick

Pick Australia when the device already fits an English academic workflow, the implanting volume you need exists there, and your next FDA interaction is weeks away rather than a full year of LATAM build. It is also the better default if you have no in-country regulatory infrastructure in Latin America and you are not willing to build it for this study.

When Latin America is the better early-feasibility pick

Pick Latin America when enrollment speed and procedure volume are the constraint — structural heart, neurovascular, and other high-volume hospital procedures — and you will treat INVIMA, ANVISA, COFEPRIS, or Panama’s CNBI-accredited pathway as a designed pathway instead of a translated Australian packet. It is also the better default when you already need a LATAM authorized representative or in-country holder for a later commercial filing. Trial import and later registro are different trámites; they reward the same discipline.

The mistake that burns both options

Copying a US protocol, swapping the letterhead, and calling it an OUS early feasibility study. Australia will make that look viable longer than it is. Latin America will often reject it earlier on a form or a translation, which feels slower and is usually cheaper than discovering after 20 patients that the protocol cannot support the IDE.

Write the protocol for the data you need FDA to accept. Then pick the country whose ethics, import, and site-activation calendar can deliver that protocol. The region is a tactic. The evidence plan is the strategy.

Talk with bioaccess® when you need the Australia-vs-LATAM call tied to a concrete early feasibility country plan and an FDA-anchored evidence drawer. Market-access work after the trial is a separate path on our market access page.

Sponsors planning a Panama first-in-human (FIH) medical-device study keep asking the same yes/no question: does MINSA require a functional large-animal study before ethics or Ministry review will move?

I am Julio Martinez-Clark, CEO of bioaccess®. Short answer: no. Functional large-animal studies are not a hard, across-the-board MINSA requirement for a Panama FIH device study. The longer answer is what you need for the dossier.

This note sits next to our live Decreto 21 of 2026 explainer and the Panama FIH device guide. It is operator guidance, not legal advice and not a quote.

One-sentence answer

Panama’s current clinical-research rulebook sets process and documentation. It does not publish a required animal n, species, duration, or GLP (Good Laboratory Practice) quota for investigational medical devices.

What the rulebook actually says

Decreto Ejecutivo No. 21 of 23 April 2026 (Gaceta Oficial No. 30510-C) implements Titles III and IV of Ley 84 of 14 May 2019. For sponsors, the decree turns on three operational gates:

• Registration on RESEGIS (MINSA’s national research-registration platform) before execution begins
• Ethics review by a committee accredited by the CNBI (Comité Nacional de Bioética de la Investigación)
• For higher-risk protocols, MINSA registration plus technical/public-health evaluation via RESEGIS, with ethics review by the accredited committee — which may run in parallel where the committee permits it

The decree also defines the documentation package — protocol, investigator’s brochure (IB), informed consent, insurance, and related files. The protocol is submitted in Spanish. It does not set a preclinical animal checklist.

What MINSA and the CNBI-accredited committee actually review

Reviewers look for a coherent risk-benefit narrative, not a species count. In practice that means:

• ISO 10993 biocompatibility evidence that is scientifically valid for the contact and duration you claim (GLP wrapping helps when you have it; it is not the only acceptable form)
• Mechanical and functional bench data that match the intended use
• Sterilization and packaging evidence for the investigational configuration
• An ISO 14971 risk file that ties residual risks to the first-in-human cohort
• An IB that documents the safety information you actually have

When the device class, contact duration, or mechanism warrants animal data, that data goes in the narrative. Animal work is a conditional element of the risk story. It is not a statute that says “run a porcine efficacy study or stop.”

How this differs from a class-specific scientific frame

Some device classes commonly use large-animal models with functional outcomes, histology, and imaging correlation — for example certain injectable or implant programs where the science community expects that evidence. Treat those models as a scientific frame for that class, not as a Panama statute. Confusing the two is how teams overbuild the wrong study or underbuild the IB.

What did not get stricter after Decreto 21

Decreto 21 of 2026 tightened process: ethics accreditation, RESEGIS registration, defined review clocks, and — for high-risk protocols — parallel ethics review where the accredited committee permits it. It did not invent a new large-animal efficacy mandate.

Operator checklist before you ask for a Panama dictamen

1. Write one page that states what preclinical evidence you have and what residual risk it leaves for first-in-human use.
2. Map each residual risk to a control in the protocol (cohort size, stopping rules, imaging, monitoring).
3. Confirm the IB and ISO 14971 file tell the same story in Spanish for the CNBI-accredited committee.
4. Register the study in RESEGIS before execution; do not treat ethics approval as a substitute for registration.
5. If you already have an animal study (or a deliberate gap), ask whether that study closes a risk the IB claims — not whether Panama “requires animals.”

Talk with bioaccess® when you need the Panama FIH dossier framed for CNBI and MINSA without inventing a statute that is not in Decreto 21.

Sponsors searching for the best countries for a structural heart early feasibility study usually want a ranked list of flags. The useful answer is a short list of decision filters, then a country shortlist that survives those filters. A structural heart early feasibility study (EFS) is a small, early human investigation of a novel cardiac device before a powered pivotal trial. Getting the geography wrong costs a protocol amendment and a missed financing window.

I am Julio Martinez-Clark, CEO of bioaccess®. This brief is for U.S. and European MedTech teams scoping structural heart EFS outside the United States. It complements the Early Feasibility Studies pillar, the EFS vs pivotal sequencing note, and the LATAM FIH startup clock. Public case patterns on bioaccessla.com (for example Axoft’s Panama first-in-human corridor for a novel implant class, and ReGelTec’s OUS path into later U.S. pivotal work) show the geography pattern — they are not structural-heart claims unless the live case study says so.

What “best country” actually means for structural heart EFS

Best is not cheapest. For structural heart, best usually means:

• Ethics and investigation authorization that can start a small cohort on a founder’s runway
• Hospitals with real cardiac imaging, cath-lab or hybrid-OR capacity, and a principal investigator who already implants in the same anatomic neighborhood
• Import rules that let an investigational device clear customs without a commercial registro sanitario
• A data posture that can support a later U.S. Investigational Device Exemption (IDE) or marketing file under 21 CFR 812.28 when the study is run under ISO 14155

Filter 1 — Regulator and ethics desks

Separate the ethics committee from the national investigation desk. Mixing them is how first patient slips a cycle. In Latin America the planning bands bioaccess® publishes for device FIH / EFS work are roughly 4–8 weeks for ethics in several corridors, with national investigation authorization commonly in a 1–3 month band after a complete dossier. Confirm every form on the agency’s current page before you file.

Country examples sponsors keep shortlisting for early device work (not a ranking, a working set): Colombia (INVIMA investigation path plus Comité de Ética en Investigación), Panama (MINSA / CNBI corridor used for several public FIH stories), El Salvador (fast startup band on the published El Salvador FIH cost and timeline page), Chile (ISP investigation authorization is not the same as Exempt Decree No. 25 commercial registro — see the Chile ISP clinical trial path), Mexico (COFEPRIS), Brazil (ANVISA), and Argentina (ANMAT). Pick from that set with the filters below, not from a tourism map.

Filter 2 — Procedure infrastructure

Structural heart EFS fails quietly when the site cannot support the implant or repair workflow. Before you fall in love with a regulator timeline, confirm:

• Echo, CT, and fluoro capacity on the study schedule
• Hybrid OR or cath-lab time that matches your enrollment plan
• Cardiac anesthesia and ICU backup for the risk class
• A principal investigator with recent volume in the adjacent commercial procedure (TAVR adjacency is not automatic qualification for a novel mitral or tricuspid device)

Filter 3 — Import and holder rules

Investigational import is not market clearance. Keep the trial file on the investigation track. If you also need commercial registration later, that is a separate Market Access / Importer of Record conversation — start at LATAM market access and Importer of record across Latin America.

Filter 4 — FDA evidence role

Write one sentence into the protocol: what this EFS must prove for the next U.S. milestone. Foreign clinical data can be considered under 21 CFR 812.28 when the study is inspectable and documented under good clinical practice. Acceptance remains FDA’s decision. Design the evidence drawer at study start: protocol, consent, monitoring, source traceability, and a clinical study report structure.

Practical shortlist pattern

For a first structural heart EFS with a small cohort and a U.S.-anchored later file, sponsors often land on one primary Latin American country plus one backup site in the same or a second country. Panama and Colombia appear repeatedly in public FIH narratives for novel implants because ethics and site activation can move inside a founder’s year. El Salvador shows up when startup calendar pressure is the binding constraint. Chile is a rigor option when the team wants ISP investigation discipline and already understands Decree 25 is a commercial track, not the trial track. Australia remains a peer comparator for some teams (rebate math, English, timezone); the honest ops comparison lives on Latin America vs Australia for FIH — use it, do not invent a rebate for Latin America that does not exist.

Operator checklist before you lock geography

1. Confirm EFS-first is the right sequencing call (see the EFS vs pivotal brief).
2. Name the procedure infrastructure the site must already have.
3. Name primary and backup countries with separate ethics and investigation owners.
4. Write the 21 CFR 812.28 evidence-role sentence into the protocol.
5. Keep commercial registro and Importer of Record work off the investigational clock unless the study truly needs a registered comparator device.

bioaccess® runs structural heart and other early device EFS work as a First-in-Human CRO with U.S. regulatory anchoring and Latin American execution. Bring the device class, the implant workflow, and the financing date — we will return a country shortlist that survives the four filters.

Sponsors keep asking whether an early feasibility study or a pivotal trial comes first as if the answer were a preference. It is not. For a novel medical device, an early feasibility study (EFS) generally comes before a pivotal trial because the two studies answer different questions.

I am Julio Martinez-Clark, CEO of bioaccess®. This is the sequencing brief I reuse when a founder wants to jump straight to a powered pivotal. It sits next to the live Early Feasibility Studies pillar, the LATAM FIH startup clock, and the FDA acceptance of Latin American data note. It is not a quote and not legal advice.

One-sentence answer

An early feasibility study comes first when clinical safety, function, or design finality is still open. A pivotal trial comes later to collect definitive safety and effectiveness evidence for a specified intended use. Skip the EFS only when nonclinical evidence already closes those unknowns and the device design is frozen.

What each study is built to answer

An EFS is a limited clinical investigation conducted early in development. Enrollment is small. The job is initial clinical safety and feasibility evidence — proof the device can be used in humans without a surprise failure mode. The U.S. Food and Drug Administration (FDA) Early Feasibility Studies Program is the U.S. framing for that IDEA under an Investigational Device Exemption (IDE) in 21 CFR Part 812.

A pivotal study is sized and powered for definitive endpoints. It assumes the device design is stable, the primary endpoint is known, and the statistical analysis plan can be written with real assumptions. If you are still learning what the right endpoint is, a pivotal protocol will be mis-scoped.

Four decision nodes

1. Risk class and novelty. Higher-risk implants and first-in-class mechanisms carry more human uncertainty. When nonclinical data alone cannot justify definitive effectiveness endpoints, EFS-first is the honest path.

2. Preclinical maturity and design finality. Is the GLP / bench / animal package enough to characterize primary safety risks? Is the device design frozen? If either answer is no, stay in EFS.

3. Funding runway. Pivotal enrollment is larger and slower. If the next financing round needs human evidence this year, a small EFS can deliver proof-of-principle without burning the pivotal budget early. That is planning math, not a guarantee.

4. Intended U.S. pathway. Map the study to the 510(k), De Novo, or Premarket Approval (PMA) evidence role you actually need. EFS does not replace pivotal evidence. A well-designed EFS can refine endpoints, validate risk controls, and feed the assumptions your later statistical analysis plan will use.

When a direct pivotal path can make sense

Lower-risk devices with a frozen design, a complete nonclinical package, and enough runway for a powered study can sometimes go straight to pivotal (or a traditional feasibility study if a thin clinical gap remains). Adding an EFS stage in that case delays marketing authorization without generating meaningfully new information.

How Latin America fits the EFS step

Many U.S. MedTech teams run the early human evidence step outside the United States, then bring a cleaner package into the U.S. IDE or marketing file. Foreign clinical data can be considered under 21 CFR 812.28 when the study is inspectable and conducted under good clinical practice. ISO 14155 is the device GCP standard we design to. Acceptance is still FDA’s call per submission — there is no automatic transfer.

In Latin America, ethics-committee review for device FIH / EFS work commonly lands in a planning band of about 4–8 weeks, and in-country investigation authorization often follows in roughly 1–3 months depending on country and dossier quality. Those are experience-based ranges from bioaccess® programs since 2010, not a promise for your protocol. The startup clock page keeps the country bands in one place.

Documentation to lock before first patient

• Protocol with an explicit evidence-role statement (what this study must do for the next regulatory or financing milestone)
• Informed consent aligned to the local ethics committee
• Monitoring and quality plan with deviation tracking
• Data management plan with source-document traceability
• Clinical study report structure and analysis framework ready at study start, not after database lock

Operator checklist

1. Write answers to the four decision nodes in one page.
2. List preclinical gaps before you pick study type.
3. Draft the evidence-role sentence your protocol will carry.
4. If EFS-first, choose the country corridor for ethics speed and cardiac or procedure infrastructure — not for tourism.
5. If you already have human feasibility evidence and a frozen design, stop debating EFS and scope the pivotal honestly.

Talk with bioaccess® when you need the sequencing call tied to a concrete FIH or EFS country plan and an FDA-anchored evidence drawer.